February, 2024
February 2024
Talha Badar: A few selected ALL abstracts to watch for at ASH23
Dec 8, 2023, 12:47

Talha Badar: A few selected ALL abstracts to watch for at ASH23

Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:

Weekend reading. ASH23, few selected ALL abstracts to watch for at this year ASH.

962: Frontline Consolidation with Nelarabine for Adults with High-Risk T-Cell ALL: Results of the Graall-2014/T Atriall Phase 2 Study. NELA did not yield an overall improved outcome; benefits were observed in MRD responders and non-ETP patients.

964: Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Pts with Ph- ALL: Preliminary Results of the GMALL Bold. Blina sequence associated with improve responses and OS.

827: Olverembatinib (3rd gen TKI) + Venetoclax and Reduced-Intensity Chemo for Pts with Newly Diagnosed Ph+ve ALL: Early Results from a Phase II Study. 31 pts enrolled, 100% CR, > 95% CMR/MMR after 3 cycle.

522: Toxicity Profile of (brexu-cel; CD19-directed CAR T-cell therapy) in Adult Pts with R/R-Cell B-ALL: Results from a Multicenter Real-World Outcomes Study. Data on 152 pts, toxicity was more common among patients with active disease. Characteristics, responses, toxicity.

965: A Phase I Study of Asciminib (ABL001) in Combination with Dasatinib and Prednisone for BCR-ABL1-Positive ALL and Blast Phase CML in Adults. IIT on 25 pts (92% were ALL). Pts characteristics and responses.

598: Loss of p53 Impairs Death Receptor Expression and Confers Resistance to CD19 CAR T-Cell in B-Cell ALL. Loss of p53 led to up to a 35% decrease in killing by CAR T treatment.

844: NGS-Based Stratification Refines the Risk Stratification in T-ALL and Identifies a Very High-Risk Subgroup of Patients. NGS-based stratification combined with WBC and MRD evaluation sharpens the prognostic classification in T-ALL.

966: Blinatumomab with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Pts with R/R B-Cell ALL: Results of a Phase I Study. 27 pts enrolled (3 mixed phenotypic), CR rate 68% (100% MRD-), 11/27 received allo-HCT, 1 yr OS 63%. Details.”

Source: Talha Badar/Twitter